These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1087 related articles for article (PubMed ID: 31150084)

  • 21. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial.
    Konstenius M; Jayaram-Lindström N; Guterstam J; Beck O; Philips B; Franck J
    Addiction; 2014 Mar; 109(3):440-9. PubMed ID: 24118269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial.
    Schönenberg M; Wiedemann E; Schneidt A; Scheeff J; Logemann A; Keune PM; Hautzinger M
    Lancet Psychiatry; 2017 Sep; 4(9):673-684. PubMed ID: 28803030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled multicenter trial on the multimodal treatment of adult attention-deficit hyperactivity disorder: enrollment and characteristics of the study sample.
    Philipsen A; Graf E; Jans T; Matthies S; Borel P; Colla M; Gentschow L; Langner D; Jacob C; Groß-Lesch S; Sobanski E; Alm B; Schumacher-Stien M; Roesler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Heinrich V; Huss M; Kornmann C; Bürger A; van Elst LT; Berger M
    Atten Defic Hyperact Disord; 2014 Mar; 6(1):35-47. PubMed ID: 24132867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
    Szobot CM; Rohde LA; Katz B; Ruaro P; Schaefer T; Walcher M; Bukstein O; Pechansky F
    Braz J Med Biol Res; 2008 Mar; 41(3):250-7. PubMed ID: 18327433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
    Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B
    Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
    Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.
    van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
    Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
    Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B
    World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
    Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
    Levin FR; Evans SM; Brooks DJ; Garawi F
    Drug Alcohol Depend; 2007 Feb; 87(1):20-9. PubMed ID: 16930863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.